News

The prevalence in New Zealand of adrenal incidentalomas, which are masses in the adrenal glands incidentally discovered during an imaging test, is similar to that of international centers, a new study found. This means that current international guidelines for managing adrenal incidentalomas likely should be applied to patients in New Zealand…

Bilateral inferior petrosal sinus sampling (IPSS) — a procedure that uses desmopressin to determine levels of ACTH hormone from veins that drain from the pituitary gland, is a sensitive way to diagnose patients with Cushing’s disease and find tumors, a Chinese study shows. The study,“Tumour Lateralization in…

Doctors often prescribe somatostatin analogs to manage the hormonal imbalance that characterizes Cushing’s syndrome. However, in rare situations these medicines have paradoxically made patients worse than better. This recently happened with a 48-year-old Spanish woman whose Cushing’s syndrome was caused by an adrenal gland tumor that was producing excess adrenocorticotropic…

Inhaled steroids can cause Cushing’s syndrome if they are combined with medications that block liver enzymes, researchers at Spain’s Hospital Son Llátzer warn in a new study. While very low levels of inhaled steroids normally reach the blood, medications blocking these liver enzymes can boost their concentration and lead to Cushing’s…

Nizoral (ketoconazole), an off-label inhibitor of steroid hormone production, can change the way the body distributes and absorbs Korlym (mifepristone), a new study finds. Because doctors sometimes prescribe both drugs simultaneously to Cushing’s syndrome patients, they need to better understand how these drugs interact to ensure the best doses…

Children’s National Health System no longer treats just kids. Its Rare Disease Institute, launched in April 2017, has partnered with the National Organization for Rare Disorders (NORD) to become the first of many U.S. “centers of excellence” to look after patients with rare diseases, regardless of age. The effort…

A long-acting, once-a-month treatment of Signifor (pasireotide) normalized cortisol levels in 40% of patients with Cushing’s disease whose disease had recurred after surgery, or who were not candidates for surgery, according to new data from a Phase 3 trial. The safety profiles of the once-monthly regimen proved to…

A rare case of Cushing’s syndrome (CS) in a 17-year-old patient with multiple pituitary adenomas highlights the importance of clinical follow-up in order to determine the best treatment options for patients. The study, “A rare case of multiple pituitary adenomas in an adolescent Cushing disease presenting as a…

The effects of obesity on the diagnosis of Cushing’s syndrome and strategies to alter the traditional approaches have been addressed in a new review study. The study, “Diagnosis and Differential Diagnosis of Cushing’s Syndrome,” appeared in The New England Journal of Medicine. The author…

More therapies are now available for the 30 million or so people with rare diseases in the U.S. than ever before, and millions of dollars are being invested in clinical studies that will test new ways of evaluating — and advancing — potential treatments, including the use of natural history…